Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.58 |
| ▸ | CD2 | P06729 | 1/20 | 0.53 |
| ▸ | CD58 | P19256 | 1/20 | 0.53 |
| ▸ | SSTR2 | P30874 | 11/20 | 0.49 |
| ▸ | SSTR5 | P35346 | 10/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 11/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 5/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 2/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22844368 | 1.00 | OXTR (0.58) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL22891909 | 0.94 | OXTR (0.59) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL23968131 | 0.94 | OXTR (0.59) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL22618578 | 0.93 | SSTR2 (0.56) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL23968133 | 0.93 | SSTR2 (0.56) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL22618582 | 0.93 | SSTR2 (0.56) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL20465752 | 0.86 | SSTR2 (0.69) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| SCHEMBL19682057 | 0.85 | OXTR (0.52) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL24348771 | 0.83 | SSTR2 (0.51) | OXTRCD2CD58SSTR2SSTR5 | |
| SCHEMBL26814255 | 0.83 | SSTR2 (0.54) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213590-B2 | SSTR-targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190262460-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | OXTR 360/4885CD2 680/4885CD58 312/4885 |
| US-20190262460-A1 | SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR3 | OXTR 83/4885CD2 403/4885CD58 954/4885 |
| US-11213590-B2 | SSTR-targeted conjugates and particles and formulations thereof | SSTR1, SSTR4, SSTR3 | OXTR 83/4885CD2 403/4885CD58 954/4885 |
| US-11160871-B2 | SSTR-targeted conjugates and particles and formulations thereof | SSTR1, SSTR4, SSTR3 | OXTR 83/4885CD2 403/4885CD58 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.